ELEVATION ONCOLOGY INC's ticker is ELEV and the CUSIP is 28623U101. A total of 32 filers reported holding ELEVATION ONCOLOGY INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,176,016 | -34.1% | 1,917,043 | +25.1% | 0.00% | – |
| Q1 2024 | $7,859,391 | +1149.6% | 1,532,045 | +30.8% | 0.00% | – |
| Q4 2023 | $628,959 | -11.3% | 1,171,246 | +9.5% | 0.00% | – |
| Q3 2023 | $708,853 | -56.6% | 1,069,805 | -0.5% | 0.00% | – |
| Q2 2023 | $1,634,239 | +88.7% | 1,075,157 | +135.9% | 0.00% | – |
| Q1 2023 | $865,984 | +173.5% | 455,781 | +36.7% | 0.00% | – |
| Q4 2022 | $316,643 | -15.8% | 333,308 | +0.1% | 0.00% | – |
| Q3 2022 | $376,000 | -33.0% | 333,024 | -16.9% | 0.00% | – |
| Q2 2022 | $561,000 | -40.8% | 400,853 | +6.6% | 0.00% | – |
| Q1 2022 | $948,000 | -58.6% | 376,153 | -1.2% | 0.00% | – |
| Q4 2021 | $2,292,000 | -55.1% | 380,813 | -41.9% | 0.00% | – |
| Q3 2021 | $5,106,000 | +527.3% | 655,409 | +992.3% | 0.00% | – |
| Q2 2021 | $814,000 | – | 60,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 2,834,910 | $7,654,257 | 3.31% |
| venBio Partners LLC | 2,434,255 | $6,572,489 | 2.84% |
| Velan Capital Investment Management LP | 597,299 | $1,612,707 | 0.92% |
| Exome Asset Management LLC | 369,322 | $997,170 | 0.87% |
| Logos Global Management LP | 3,850,000 | $10,395,000 | 0.84% |
| TANG CAPITAL MANAGEMENT LLC | 3,060,000 | $8,262,000 | 0.84% |
| Palo Alto Investors LP | 1,800,106 | $4,860,286 | 0.56% |
| Darwin Global Management, Ltd. | 1,916,290 | $4,809,888 | 0.56% |
| Ghost Tree Capital, LLC | 600,000 | $1,620,000 | 0.51% |
| Affinity Asset Advisors, LLC | 1,468,825 | $3,965,828 | 0.46% |